Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ibio Inc (IBIO)

Ibio Inc (IBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,397
  • Shares Outstanding, K 34,544
  • Annual Sales, $ 400 K
  • Annual Income, $ -18,380 K
  • EBIT $ -20 M
  • EBITDA $ -19 M
  • 60-Month Beta 1.36
  • Price/Sales 168.40
  • Price/Cash Flow N/A
  • Price/Book 1.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 4
  • High Estimate $-0.04
  • Low Estimate $-0.07
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) +87.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4300 +42.66%
on 03/26/26
2.7450 -25.68%
on 03/13/26
-0.5700 (-21.84%)
since 03/06/26
3-Month
1.4300 +42.66%
on 03/26/26
3.1300 -34.82%
on 02/26/26
-0.0200 (-0.97%)
since 01/06/26
52-Week
0.5562 +266.77%
on 08/08/25
3.8200 -46.60%
on 12/10/25
-1.1850 (-36.74%)
since 04/04/25

Most Recent Stories

More News
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company...

IBIO : 2.0400 (+3.03%)
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical...

IBIO : 2.0400 (+3.03%)
iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer...

IBIO : 2.0400 (+3.03%)
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New Preclinical Data and Scientific Presentations...

IBIO : 2.0400 (+3.03%)
iBio Announces $26 Million Private Placement

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement...

IBIO : 2.0400 (+3.03%)
iBio to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore...

IBIO : 2.0400 (+3.03%)
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Strengthened cash position and extended runway  into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds ...

IBIO : 2.0400 (+3.03%)
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation...

IBIO : 2.0400 (+3.03%)
Why Armata Pharmaceuticals Skyrocketed 370% Today

Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on the back of groundbreaking mid-stage clinical results for its bacteriophage-based...

ESLA : 1.3800 (+31.43%)
SLP : 12.21 (+1.83%)
ARMP : 11.48 (+12.77%)
BNBX : 0.6389 (-2.68%)
IBIO : 2.0400 (+3.03%)
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and...

IBIO : 2.0400 (+3.03%)

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

3rd Resistance Point 2.1767
2nd Resistance Point 2.0933
1st Resistance Point 2.0367
Last Price 2.0400
1st Support Level 1.8967
2nd Support Level 1.8133
3rd Support Level 1.7567

See More

52-Week High 3.8200
Fibonacci 61.8% 2.5732
Fibonacci 50% 2.1881
Last Price 2.0400
Fibonacci 38.2% 1.8030
52-Week Low 0.5562

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.